Drug intelligence / Profile preview

REC-4209

Development stage: Discontinued
Lead developer: Recursion Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

REC-4209 is an oral, reversible small molecule drug candidate developed by Recursion Pharmaceuticals for the treatment of idiopathic pulmonary fibrosis (IPF). Discovered using Recursion's AI-driven drug discovery platform, the compound was internally referred to by the codename 'Epsilon.' Although it reached the IND-enabling stage, Recursion ultimately terminated the program as part of a strategic pipeline prioritization to focus on oncology and rare diseases. The specific biological target of REC-4209 remains undisclosed.

Beyond the preview

Go deeper on REC-4209.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REC-4209.

Explore the full profile